Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, looks at a new approach to evaluating innovative MedTech.
The UK’s regulatory and health‑service landscape has taken a significant step forward with the launch (2nd September 2026) of a new partnership between the Medicines and Healthcare products Regulatory Agency (MHRA) and Manchester University NHS Foundation Trust (MFT).
The collaboration establishes the Manchester Sandbox, a real‑world testbed designed to evaluate emerging technologies — particularly AI‑enabled medical devices — in live NHS environments. For industry, regulators and clinicians, the initiative marks a notable shift toward lifecycle‑based regulation and evidence generation that reflects how technologies actually perform in practice.
The announcement comes at a moment when the NHS is under pressure to adopt innovation more rapidly, while maintaining public trust in safety and effectiveness. Sandboxes have been used in other regulated sectors for years, but their application to health technologies is still emerging. The MHRA’s move to embed a major sandbox within one of the UK’s largest NHS trusts signals a more ambitious, system‑level approach to bridging the gap between promising prototypes and proven clinical tools.
A Real‑World Evidence Engine for AI and Emerging Technologies
At the core of the Manchester Sandbox is a simple but powerful proposition: technologies that show promise in development must be tested in real clinical settings if patients are to benefit sooner. The programme will allow innovators to deploy tools — including AI‑enabled medical devices — directly within MFT’s care pathways, under controlled conditions and with regulatory oversight.
Early candidates include risk‑stratification algorithms capable of identifying patients at higher risk of complications from long‑term conditions. These tools are often difficult to validate using traditional trial designs, which struggle to capture the complexity of real‑world workflows, clinician behaviour and patient diversity. By situating evaluation within day‑to‑day practice, the sandbox aims to generate evidence on safety, performance and impact that is both more practical and more relevant to NHS adoption decisions.
Manchester’s Growing Role as a National Innovation Hub
Manchester’s selection is strategic. The city region has spent the past decade building a reputation as one of the UK’s most advanced health‑innovation ecosystems. MFT is one of the country’s largest NHS trusts, with deep research partnerships, strong digital infrastructure and a rapidly expanding AI sector. The region’s integrated approach — spanning universities, industry, clinicians and regulators — makes it well suited to host a programme that depends on collaboration across institutional boundaries.
The launch event at MFT’s Oxford Road Campus showcased emerging technologies already in use locally, including wearables and AI‑powered ambient voice tools designed to support earlier intervention and reduce administrative burden. These demonstrations underscored the region’s ambition not only to test innovation but to embed it into care pathways at scale.
A New Model for National Adoption
One of the most significant aspects of the Manchester Sandbox is its explicit national remit. Learning generated through the programme will be shared across the NHS, informing how new technologies are introduced in other regions. This creates a potential blueprint for future adoption pathways, particularly for AI‑enabled devices where evidence requirements are still evolving.
For developers, the sandbox offers clarity on what “good evidence” looks like for NHS use. Many innovators struggle to understand the practical data needed to demonstrate safety, effectiveness and workflow fit. By working directly with clinicians and regulators, companies can refine their products earlier and reduce the risk of late‑stage failure.
For the NHS, the sandbox provides a mechanism to evaluate technologies more quickly and more safely, reducing the time between innovation and patient benefit. It also supports more informed procurement and commissioning decisions, ensuring that only technologies that genuinely improve care are scaled.
Political and Regulatory Signals
The partnership carries clear political backing. Health Innovation Minister James Frith emphasised that Manchester is “leading the way” in getting proven technologies to patients faster, while reiterating that innovation must not compromise safety. His comments reflect the government’s broader narrative: the UK can be a global leader in health innovation, but only if regulatory confidence keeps pace with technological change.
MHRA Chief Executive Lawrence Tallon reinforced the regulator’s commitment to enabling safe innovation. He highlighted the challenge of understanding how AI works “in practice” — a recognition that laboratory performance often diverges from real‑world behaviour. The sandbox is designed to close that gap.
MFT Chief Executive Mark Cubbon framed the initiative in terms of patient trust: access and safety must go hand in hand. By creating a clearer route from innovation to adoption, he argued, the NHS can deliver faster access to technologies that improve care while maintaining high safety standards.
Next Steps: Roundtables and Industry Engagement
Later this year, MHRA and MFT will convene a roundtable bringing together regulators, providers, innovators, researchers and patient representatives to shape the next wave of projects. The MHRA will also invite expressions of interest from MedTech developers seeking to participate in future sandbox phases.
The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
